Antoine Pau started his career at Novartis Pharma in the Business Planning Analysis department (Oncology Business Unit). He then joined Mazars as financial auditor where he worked for three years managing the legal audits of pharmaceutical and biotech companies, as well as private equity funds, and also conducted financial due diligences for tech companies in the Transaction Services department. He joined Truffle Capital in 2008, where he holds the position of Life Sciences Partner.
Board member of Theradiag (Alternext: ALTER), Vexim (Alternext: ALVXM), Abivax, Biokinesis, Deinobiotics and Diaccurate.
A PharmD and an ESSEC graduate (MSc in Management), Antoine is also an adjunct lecturer at Sciences Po Paris.